Cancer vaccine biotech CimCure raises €5 million in seed round investment

CimCure, a biotech spin-off of Amsterdam UMC, focusing on the development of a novel vaccine-based cancer immunotherapy through its Immune-Boost (iBoost) technology, announced that it has raised little over € 5 million in a financing Seed Round led by Dutch VC Positron Ventures.

The round was supported by several investors with deep industry knowledge, including the investment vehicle of Tom Würdinger, professor at Amsterdam UMC. With the proceeds of this Seed Round CimCure will further advance the vaccine up until phase 1-2 clinical studies in humans. Dutch vaccine CDMO Intravacc will be CimCure’s partner for the development and production of the lead compound.

Cancer vaccine biotech CimCure raises €5 million in seed round investment

The vaccine-based immunotherapy developed by the team of Prof. Dr Griffioen at the Amsterdam UMC and licensed to CimCure has shown high effectiveness and safety, both in murine animal models and in an efficacy study in client-owned dogs with spontaneous bladder cancer. In late May, some of the research results which underlie CimCure’s innovation were published in Nature Communications (Van Beijnum et al, 2022).

CimCure was founded in 2016 as a spin-off of Amsterdam UMC supported by Amsterdam UMC’s TTO Innovation Exchange Amsterdam and is led by Prof. dr. Arjan Griffioen, CSO, and Diederik Engbersen, CEO. Both have extensive experience in the biotech industry and started the company to commercialise a smart, effective and safe treatment strategy against all types of solid tumours at all stages, and can be combined with conventional and state-of-the-art anti-cancer strategies.

Joseph Peeraer, founding partner of Positron said:

“We feel privileged to be able to invest in this promising iBoost technology and vaccine-based cancer immunotherapy, which might become a real game-changer in the fight against cancer. This investment in CimCure exemplifies our thesis to invest at an early stage in outstanding scientists who would like to bring potentially groundbreaking and impactful innovation to market. Professor Griffioen’s invention may lead to much less demanding, cheaper and more effective cancer treatment.”

Diederik Engbersen, CimCure’s CEO, said:

“We are pleased with this funding round led by Positron and supported by Tom Würdinger. Our first promising findings with murine animal models and client-owned dogs have recently been published in Nature Communications, bolstering our commitment to advance our technology and therapy towards clinical trials and cancer patients globally over the coming years.”